APA (7th ed.) Citation

Böhm, M., Anker, S., Mahfoud, F., Lauder, L., Filippatos, G., Ferreira, J. P., . . . Butler, J. (2023). Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: The EMPEROR-Preserved trial : clinical research : heart failure and cardiomyopathies. European heart journal, 44(5), . https://doi.org/10.1093/eurheartj/ehac693

Chicago Style (17th ed.) Citation

Böhm, Michael, et al. "Empagliflozin, Irrespective of Blood Pressure, Improves Outcomes in Heart Failure with Preserved Ejection Fraction: The EMPEROR-Preserved Trial : Clinical Research : Heart Failure and Cardiomyopathies." European Heart Journal 44, no. 5 (2023). https://doi.org/10.1093/eurheartj/ehac693.

MLA (9th ed.) Citation

Böhm, Michael, et al. "Empagliflozin, Irrespective of Blood Pressure, Improves Outcomes in Heart Failure with Preserved Ejection Fraction: The EMPEROR-Preserved Trial : Clinical Research : Heart Failure and Cardiomyopathies." European Heart Journal, vol. 44, no. 5, 2023, https://doi.org/10.1093/eurheartj/ehac693.